MAP2K7 and lung carcinoma: Our novel findings that PF‐06260933 significantly suppressed lung cancer cell functions and had synergistic inhibitory effect with MEK inhibitor on lung cancer cell proliferation suggest that MAP4K4‐specific inhibition could be a promising approach to treating lung adenocarcinoma.